Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome

Leuk Res. 2007 Oct;31(10):1343-9. doi: 10.1016/j.leukres.2007.01.018. Epub 2007 Mar 12.

Abstract

We analyzed cytosolic high-Km 5'-nucleotidase (cN-II) and deoxycytidine kinase (dCK) mRNA expression in bone marrow mononuclear cells (BMMNC) of patients with high-risk myelodysplastic syndrome (MDS) using quantitative real-time polymerase chain reaction (rt-PCR). At diagnosis, the cN-II mRNA expression of patients was higher than that of healthy volunteers, but the dCK mRNA expression showed no significant difference. Patients with ara-C-containing chemotherapies whose BMMNC showed a high level of cN-II expression (greater than the median value) had shorter median overall survival (15 months versus 22 months, p<0.01) and shorter median post-chemotherapy survival (10 months versus 16 months, p=0.012). These data suggest that the expression level of cN-II mRNA might be a prognostic factor of high-risk MDS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 5'-Nucleotidase / biosynthesis*
  • 5'-Nucleotidase / genetics
  • Antimetabolites, Antineoplastic / therapeutic use
  • Bone Marrow Cells / metabolism
  • Cytarabine / therapeutic use
  • Deoxycytidine Kinase / biosynthesis
  • Deoxycytidine Kinase / genetics
  • Humans
  • Kaplan-Meier Estimate
  • Leukocytes, Mononuclear / metabolism
  • Myelodysplastic Syndromes / drug therapy
  • Myelodysplastic Syndromes / enzymology*
  • Myelodysplastic Syndromes / genetics
  • Precancerous Conditions / enzymology
  • Precancerous Conditions / genetics
  • Prognosis
  • RNA, Messenger / analysis
  • RNA, Messenger / biosynthesis*
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Antimetabolites, Antineoplastic
  • RNA, Messenger
  • Cytarabine
  • Deoxycytidine Kinase
  • 5'-Nucleotidase
  • NT5C2 protein, human